LPA and atherosclerosis: The phase 2 randomized, double-blind, placebo-controlled Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction-Dose Finding Study (OCEAN(a)-DOSE trial; NCT04270760) enrolled 281 patients with established ASCVD and baseline Lp(a) levels >150 nmol/L receiving either olpasiran (10 mg every 12 weeks, 75 mg every 12 weeks, 225 mg every 12 weeks, or 225 mg every 24 weeks) or a placebo [49].